艾滋病毒感染者妇女的医疗保健自主权。
Health Care Autonomy of Women Living with HIV.
机构信息
From the Office of the Director (R.R.R.), the Center for Global Health, Division of Global HIV and Tuberculosis (S.M., H.L.T.), and the National Center on Birth Defects and Developmental Disabilities, Division of Congenital and Developmental Disorders (C.A.M., A.D., M.A.H.), Centers for Disease Control and Prevention, Atlanta.
出版信息
N Engl J Med. 2019 Aug 29;381(9):798-800. doi: 10.1056/NEJMp1908843. Epub 2019 Jul 24.
Abstract
In sub-Saharan Africa, more than 60% of all adults living with HIV in 2018 were women, according to the Joint United Nations Programme on HIV and AIDS (https://aidsinfo.unaids.org).
摘要
在撒哈拉以南非洲，根据联合国艾滋病规划署（https://aidsinfo.unaids.org）的数据，2018 年，所有感染艾滋病毒的成年人中，超过 60%是女性。
相似文献
1
Health Care Autonomy of Women Living with HIV.艾滋病毒感染者妇女的医疗保健自主权。
N Engl J Med. 2019 Aug 29;381(9):798-800. doi: 10.1056/NEJMp1908843. Epub 2019 Jul 24.
2
Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception.受孕时使用多替拉韦治疗导致的神经管缺陷。
N Engl J Med. 2018 Sep 6;379(10):979-981. doi: 10.1056/NEJMc1807653. Epub 2018 Jul 24.
3
Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana.博茨瓦纳的神经管缺陷和抗逆转录病毒治疗方案。
N Engl J Med. 2019 Aug 29;381(9):827-840. doi: 10.1056/NEJMoa1905230. Epub 2019 Jul 22.
4
Assessing the risk of dolutegravir for women of childbearing potential.评估多替拉韦对有生育潜力女性的风险。
Lancet Glob Health. 2018 Sep;6(9):e958-e959. doi: 10.1016/S2214-109X(18)30326-7. Epub 2018 Jul 23.
5
Is There a Safety Signal for Dolutegravir and Integrase Inhibitors During Pregnancy?在妊娠期间，多拉韦林和整合酶抑制剂是否存在安全信号？
J Acquir Immune Defic Syndr. 2019 Aug 1;81(4):481-486. doi: 10.1097/QAI.0000000000002065.
6
Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects.优化妊娠期药物安全性信号的反应：以多替拉韦和神经管缺陷为例。
J Int AIDS Soc. 2019 Jul;22(7):e25352. doi: 10.1002/jia2.25352.
7
Associations Between Antiretroviral Regimen and Changes in Blood Pressure: Results From the D2EFT Study.抗逆转录病毒治疗方案与血压变化之间的关联：D2EFT研究结果
Clin Infect Dis. 2025 Feb 5;80(1):160-163. doi: 10.1093/cid/ciae256.
8
Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study.多替拉韦和依非韦伦方案对有生育潜力的南非 HIV 感染妇女的风险与获益：一项建模研究。
Ann Intern Med. 2019 May 7;170(9):614-625. doi: 10.7326/M18-3358. Epub 2019 Apr 2.
9
Dolutegravir for second-line antiretroviral therapy: the beat goes on.多替拉韦用于二线抗逆转录病毒治疗：持续前行。
Lancet Glob Health. 2024 Feb;12(2):e183-e184. doi: 10.1016/S2214-109X(23)00569-7. Epub 2023 Dec 21.
10
Increase in Body Mass Index in Children With HIV, Switched to Tenofovir Alafenamide Fumarate or Dolutegravir Containing Antiretroviral Regimens.换用富马酸替诺福韦艾拉酚胺或含多替拉韦的抗逆转录病毒方案的HIV感染儿童体重指数增加
Pediatr Infect Dis J. 2021 May 1;40(5):e215-e216. doi: 10.1097/INF.0000000000003076.
引用本文的文献
1
Overcoming Ethical Challenges to Engaging Men Who Have Sex with Women in HIV Research.克服在 HIV 研究中让与女性发生性行为的男性参与的伦理挑战。
AIDS Behav. 2021 Dec;25(12):4055-4060. doi: 10.1007/s10461-021-03185-0. Epub 2021 Feb 13.
2
Cervical Cancer Screening among Women Receiving Antiretroviral Therapy in a Resource-Limited Environment.资源有限环境下接受抗逆转录病毒疗法的女性的宫颈癌筛查。
Asian Pac J Cancer Prev. 2020 Jul 1;21(7):2035-2045. doi: 10.31557/APJCP.2020.21.7.2035.
本文引用的文献
1
Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting.一线包含整合酶抑制剂（INSTIs）的方案的持久性：来自真实环境的数据。
J Antimicrob Chemother. 2019 May 1;74(5):1363-1367. doi: 10.1093/jac/dky566.
2
Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception.受孕时使用多替拉韦治疗导致的神经管缺陷。
N Engl J Med. 2018 Sep 6;379(10):979-981. doi: 10.1056/NEJMc1807653. Epub 2018 Jul 24.
3
Editorial In Bed with The Devil: Recognizing Human Teratogenic Exposures.社论：与魔鬼共眠——识别对人类有致畸作用的暴露因素
Birth Defects Res. 2017 Nov 1;109(18):1407-1413. doi: 10.1002/bdr2.1134.
4
Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV.多替拉韦——关于其治疗HIV的药理学、疗效及安全性的综述
Drug Des Devel Ther. 2015 Jul 7;9:3547-55. doi: 10.2147/DDDT.S84850. eCollection 2015.
5
Evolving knowledge of the teratogenicity of medications in human pregnancy.在人类妊娠中药物致畸性的知识不断发展。
Am J Med Genet C Semin Med Genet. 2011 Aug 15;157C(3):175-82. doi: 10.1002/ajmg.c.30313. Epub 2011 Jul 15.
Zotero 插件